Paring down the placebo response

descriptionPublicationkeyboard_double_arrow_right Article 29 Nov 2016 English Publisher:Springer Science and Business Media LLCJournal:Nature Reviews Drug Discovery, volume 15, pages 807-808 (issn: 1474-1776, eissn: 1474-1784,

Copyright policy )

Authors: Asher, Mullard;

doi: 10.1038/nrd.2016.255

pmid: 27895331

Paring down the placebo response

- Summary
- Subjects
- Metrics

Abstract

Pivotal trials of Alkermes's antidepressant ALKS 5461 show how a patented clinical trial design might be able to help control problematic placebo responses. Pivotal trials of Alkermes's antidepressant ALKS 5461 show how a patented clinical trial design might be able to help control problematic placebo responses.

Keywords

Psychotropic Drugs, Research Design, Drug Design, Humans, Placebo Effect, Randomized Controlled Trials as Topic

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	3
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average